MX2021010492A - Uso de la 2-fucosil-lactosa para aumentar la funcionalidad cerebral. - Google Patents

Uso de la 2-fucosil-lactosa para aumentar la funcionalidad cerebral.

Info

Publication number
MX2021010492A
MX2021010492A MX2021010492A MX2021010492A MX2021010492A MX 2021010492 A MX2021010492 A MX 2021010492A MX 2021010492 A MX2021010492 A MX 2021010492A MX 2021010492 A MX2021010492 A MX 2021010492A MX 2021010492 A MX2021010492 A MX 2021010492A
Authority
MX
Mexico
Prior art keywords
methods
fucosyl
lactose
increasing brain
brain functionality
Prior art date
Application number
MX2021010492A
Other languages
English (en)
Inventor
Perez Alejandro Barranco
Gonzalez Maria Ramirez
Rachael Buck
Hernandez Enrique Vazquez
Cabrera Ricardo Rueda
Original Assignee
Abbott Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46940437&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2021010492(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Abbott Lab filed Critical Abbott Lab
Publication of MX2021010492A publication Critical patent/MX2021010492A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/125—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives containing carbohydrate syrups; containing sugars; containing sugar alcohols; containing starch hydrolysates
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/40—Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Nutrition Science (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Pediatric Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)

Abstract

Se describen métodos para mejorar el aprendizaje y/o la memoria, mejorar la adquisición de la memoria, la retención y recuperación de la memoria induciendo una mayor potenciación a largo plazo en la sinapsis neuronal hipocámpica en los individuos. Los métodos incluyen la administración de 2-fucosil-lactosa a un individuo.
MX2021010492A 2012-09-14 2015-03-13 Uso de la 2-fucosil-lactosa para aumentar la funcionalidad cerebral. MX2021010492A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP12382356.9A EP2708147B1 (en) 2012-09-14 2012-09-14 Methods for increasing brain functionality using 2-fucosyl-lactose

Publications (1)

Publication Number Publication Date
MX2021010492A true MX2021010492A (es) 2021-10-01

Family

ID=46940437

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2015003425A MX2015003425A (es) 2012-09-14 2013-09-12 Metodos para aumentar la funcionalidad cerebral al usar 2-fucosil-lactosa.
MX2021010492A MX2021010492A (es) 2012-09-14 2015-03-13 Uso de la 2-fucosil-lactosa para aumentar la funcionalidad cerebral.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2015003425A MX2015003425A (es) 2012-09-14 2013-09-12 Metodos para aumentar la funcionalidad cerebral al usar 2-fucosil-lactosa.

Country Status (13)

Country Link
US (1) US10398715B2 (es)
EP (2) EP3704957A1 (es)
CN (1) CN104780785A (es)
BR (1) BR112015005794A2 (es)
CA (1) CA2884634A1 (es)
DK (1) DK2708147T3 (es)
ES (1) ES2795665T3 (es)
IL (1) IL237617A0 (es)
MX (2) MX2015003425A (es)
MY (1) MY180148A (es)
PH (1) PH12015500546A1 (es)
SG (1) SG11201501893XA (es)
WO (1) WO2014043368A1 (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2708145T3 (en) 2012-09-14 2016-07-18 Abbott Lab Nutritional Compositions for Use in Methods to Modulate Corticosterone Levels in Psychologically Stressed Individuals
EP2888950A1 (en) * 2013-12-24 2015-07-01 Abbott Laboratories Methods for treating, preventing, or reducing neuroinflammation or cognitive impairment
EP3223825A1 (en) * 2014-11-26 2017-10-04 Abbott Laboratories Infant formula comprising human milk oligosaccharides, polyunsaturated fatty acids, nucleotides, and lutein
MX2017006701A (es) * 2014-11-26 2018-02-13 Abbott Lab Fórmula infantil con rrr-alfa-tocoferol,2'-fucosilactosa y un probiótico.
PL3368046T3 (pl) 2015-10-28 2022-11-28 Glycom A/S Syntetyczna kompozycja i sposób modulowania funkcji mózgu i zachowania
US10780103B2 (en) 2015-10-28 2020-09-22 Glycom A/S Synthetic composition and method for modulating emotion and mood disorders
KR101731263B1 (ko) 2016-04-25 2017-05-02 서울대학교 산학협력단 코리네박테리움 글루타미쿰을 이용한 2'-푸코실락토오스의 생산방법
WO2017215722A1 (en) * 2016-06-15 2017-12-21 Glycom A/S Synthetic composition comprising hmo and method for modulating emotion and mood disorders
JP2019523278A (ja) 2016-07-28 2019-08-22 フォンテラ コ−オペレイティブ グループ リミティド 乳製品およびプロセス
CN110799045A (zh) * 2017-05-24 2020-02-14 雀巢产品有限公司 用于改善短期记忆和其他认知益处的包含人乳低聚糖(hmo)的组合物
RU2019141902A (ru) * 2017-05-24 2021-06-17 Сосьете Де Продюи Нестле С.А. Композиция, содержащая олигофруктозу (of), для применения в улучшении кратковременной памяти и получении других когнитивных преимуществ
WO2018215406A1 (en) 2017-05-24 2018-11-29 Nestec S.A. A nutritional composition for use to enhance attention and/or reduce impulsivity
KR101953375B1 (ko) * 2017-11-20 2019-02-28 고려대학교 산학협력단 다양하고 신규한 퓨코실 올리고당의 제조법 및 이의 용도
KR20190130720A (ko) * 2018-05-15 2019-11-25 (주)에이피테크놀로지 2'-푸코실락토오스를 포함하는 뇌졸중 예방용 조성물
MX2021010289A (es) * 2019-03-05 2022-02-10 Glycom As Oligosacaridos de leche humana para uso en el mejoramiento de la funcion ejecutiva.
WO2022117710A1 (en) 2020-12-04 2022-06-09 Société des Produits Nestlé S.A. Stable aqueous composition for preterm to promote early postnal growth
CN114223723A (zh) * 2021-12-13 2022-03-25 黑龙江飞鹤乳业有限公司 营养组合物、包含其的食品以及该营养组合物的用途
KR102570073B1 (ko) * 2022-11-17 2023-08-24 (주)에이피테크놀로지 2'-푸코실락토오스를 포함하는 치매 개선 또는 치료용조성물
CN118105395A (zh) * 2023-12-29 2024-05-31 澳优乳业（中国）有限公司 低聚糖2’-fl在制备用于改善神经发育和改善功能障碍的产品中的应用

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995024494A1 (en) * 1994-03-09 1995-09-14 Abbott Laboratories Humanized milk
DK0782573T3 (da) * 1994-09-20 2000-06-05 Univ California Brefeldin og analoger til forbedret synaptisk transmission
IL131126A (en) 1997-02-21 2003-04-10 Abbott Lab Compositions for reducing the incidence of necrotizing enterocolitis and the preparation thereof
US6365218B1 (en) 2000-02-04 2002-04-02 Abbott Laboratories Pediatric formula and methods for providing nutrition and improving tolerance
US6811801B2 (en) 2001-12-12 2004-11-02 Abbott Laboratories Methods and compositions for brightening the color of thermally processed nutritionals
EP2173369A2 (en) * 2003-08-08 2010-04-14 DSM IP Assets B.V. Novel method for screening brain-active compounds
WO2008011538A2 (en) * 2006-07-19 2008-01-24 The Salk Institute For Biological Studies Methods of using flavonoids to enhance memory
US9034314B2 (en) * 2008-11-03 2015-05-19 Nestec S.A. Nutritional composition comprising probiotics and improving sleep patterns
JP2012522827A (ja) * 2009-04-07 2012-09-27 グリコム・アクティーゼルスカブ ２’−ｏ−フコシルラクトースの合成方法
DK2451462T3 (en) 2009-07-06 2017-12-11 Children's Hospital Medical Center Inhibition of inflammation with milk oligosaccharides
CA2822497C (en) 2010-12-31 2020-07-28 Abbott Laboratories Methods for reducing the incidence of oxidative stress using human milk oligosaccharides, vitamin c and anti-inflammatory agents
BR112013016914A2 (pt) * 2010-12-31 2019-09-24 Abbott Lab combinação simbiótica de probióticos e oligossacarídeos do leite humano para promover o crescimento de microbiota benéfica
WO2012092158A1 (en) * 2010-12-31 2012-07-05 Abbott Laboratories Human milk oligosaccharides for modulating inflammation
MY192208A (en) * 2010-12-31 2022-08-08 Abbott Lab Nutritional formulations including human milk oligosaccharides and antioxidants and uses thereof
CN108741083A (zh) * 2010-12-31 2018-11-06 雅培制药有限公司 促进有益细菌生长的中性人乳寡糖
SG10201603856PA (en) * 2010-12-31 2016-07-28 Abbott Lab Methods For Decreasing The Incidence Of Necrotizing Enterocolitis In Infants, Toddlers, Or Children Using Human Milk Oligosaccharides
MY170185A (en) 2011-10-18 2019-07-09 Nestle Sa Composition for use in brain growth and/or cognitive and/or psychomotor development
DK2708145T3 (en) 2012-09-14 2016-07-18 Abbott Lab Nutritional Compositions for Use in Methods to Modulate Corticosterone Levels in Psychologically Stressed Individuals

Also Published As

Publication number Publication date
BR112015005794A2 (pt) 2017-07-04
MY180148A (en) 2020-11-23
EP2708147B1 (en) 2020-03-11
EP2708147A8 (en) 2014-09-03
EP2708147A1 (en) 2014-03-19
DK2708147T3 (da) 2020-05-18
ES2795665T3 (es) 2020-11-24
IL237617A0 (en) 2015-04-30
SG11201501893XA (en) 2015-04-29
EP3704957A1 (en) 2020-09-09
PH12015500546A1 (en) 2015-05-11
CN104780785A (zh) 2015-07-15
WO2014043368A1 (en) 2014-03-20
US20150231159A1 (en) 2015-08-20
CA2884634A1 (en) 2014-03-20
US10398715B2 (en) 2019-09-03
MX2015003425A (es) 2015-06-22

Similar Documents

Publication Publication Date Title
PH12015500546A1 (en) Methods for increasing brain functionality using 2-fucosyl-lactose
HK1250620A1 (zh) 假體瓣膜、框架和小葉及其方法
HK1249002B (zh) 改進的具有小葉支架的假體心臟瓣膜
HK1215149A1 (zh) 人工心瓣葉片中的平面區域
EP3010448A4 (en) Prosthetic heart valve with linking element and methods for implanting same
ZA201500887B (en) Human anti-cd27 antibodies, methods and uses
CA139448S (en) Stimulation device
GB201200075D0 (en) Grf3 mutants, methods and plants
HK1170901A2 (en) A smart adjustable human body model
GB201020616D0 (en) Device for imparting distance information
IL242224B (en) Methods for obtaining retinal progenitors, retinal pigmented epithelial cells and neural retinal cells
HK1203801A1 (en) Dental post for supporting dental prostheses, and method for the production thereof
SG11201508115TA (en) Rewriteable aberration-corrected gradient-index intraocular lenses
EP3230439A4 (en) Human blood brain barrier model
EP2901848A4 (en) MASSIVE FIBER BODY AND ARTIFICIAL EARTH OF SOLID FIBER BODY
EP3191172A4 (en) Nerve cuff electrode for neuromodulation in large human nerve trunks
CA152179S (en) Analytical apparatus for drug testing
IL245086A0 (en) Retaining matrix system and dental implant
EP3005981A4 (en) IMPLANTABLE LENS FOR MYOPIA AND METHOD FOR PREPARING SAID LENS
WO2014179771A8 (en) Dosing combinations for reducing undesired humoral immune responses
EP2865666A4 (en) HEXAHYDROPENTALENE DERIVATIVES, METHOD OF MANUFACTURE AND USE IN MEDICINE
WO2014135878A3 (en) Methods for treating cells with immunosuppressants to enhance their immunosuppressive potency
EP2952160A4 (en) ORGANIC LIGHT TREATMENT SYSTEM, AND ENDOPROTHESIS
AU2013904589A0 (en) System and method for the capture and representation of the logic, structure, pattern and emotion of daily interactions as a habit, sequence or a regular course of procedure in the daily routine of people with disabilities
AU2013902173A0 (en) Identity Crisis Education Recovery Model Compartments Voices Therapy